Vir Biotechnology Stock Probability of Future Stock Price Finishing Over 7.4
| VIR Stock | USD 7.47 0.07 0.95% |
Vir |
Vir Biotechnology Target Price Odds to finish over 7.4
The tendency of Vir Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay above $ 7.40 in 90 days |
| 7.47 | 90 days | 7.40 | about 72.83 |
Based on a normal probability distribution, the odds of Vir Biotechnology to stay above $ 7.40 in 90 days from now is about 72.83 (This Vir Biotechnology probability density function shows the probability of Vir Stock to fall within a particular range of prices over 90 days) . Probability of Vir Biotechnology price to stay between $ 7.40 and its current price of $7.47 at the end of the 90-day period is under 4.
Considering the 90-day investment horizon Vir Biotechnology has a beta of 0.43. This entails as returns on the market go up, Vir Biotechnology average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Vir Biotechnology will be expected to be much smaller as well. Additionally Vir Biotechnology has an alpha of 0.0546, implying that it can generate a 0.0546 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Vir Biotechnology Price Density |
| Price |
Predictive Modules for Vir Biotechnology
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Vir Biotechnology. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Vir Biotechnology Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Vir Biotechnology is not an exception. The market had few large corrections towards the Vir Biotechnology's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Vir Biotechnology, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Vir Biotechnology within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.05 | |
β | Beta against Dow Jones | 0.43 | |
σ | Overall volatility | 0.79 | |
Ir | Information ratio | 0.01 |
Vir Biotechnology Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Vir Biotechnology for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Vir Biotechnology can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Vir Biotechnology had very high historical volatility over the last 90 days | |
| The company reported the last year's revenue of 86.18 M. Reported Net Loss for the year was (615.06 M) with profit before taxes, overhead, and interest of 1.03 B. | |
| Vir Biotechnology has about 2.2 B in cash with (778.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.55, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Vir Biotechnology has a poor financial position based on the latest SEC disclosures | |
| Roughly 74.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta |
Vir Biotechnology Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Vir Stock often depends not only on the future outlook of the current and potential Vir Biotechnology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Vir Biotechnology's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 134.1 M | |
| Cash And Short Term Investments | 1.5 B |
Vir Biotechnology Technical Analysis
Vir Biotechnology's future price can be derived by breaking down and analyzing its technical indicators over time. Vir Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Vir Biotechnology. In general, you should focus on analyzing Vir Stock price patterns and their correlations with different microeconomic environments and drivers.
Vir Biotechnology Predictive Forecast Models
Vir Biotechnology's time-series forecasting models is one of many Vir Biotechnology's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Vir Biotechnology's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Vir Biotechnology
Checking the ongoing alerts about Vir Biotechnology for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Vir Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Vir Biotechnology had very high historical volatility over the last 90 days | |
| The company reported the last year's revenue of 86.18 M. Reported Net Loss for the year was (615.06 M) with profit before taxes, overhead, and interest of 1.03 B. | |
| Vir Biotechnology has about 2.2 B in cash with (778.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.55, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Vir Biotechnology has a poor financial position based on the latest SEC disclosures | |
| Roughly 74.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta |
Additional Tools for Vir Stock Analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.